DEXA Body Composition Scan for Mounjaro, Ozempic & Wegovy: Track Fat Loss, Muscle & Visceral Fat

Weight loss medications such as Mounjaro, Ozempic, and Wegovy have transformed obesity treatment. As a result, patients are now achieving significant weight loss that was previously difficult with lifestyle changes alone.

However, there’s an important question many people overlook:

What exactly are you losing — fat, muscle, or both?

This is precisely where a DEXA body composition scan becomes essential.

Most patients track progress using weight or BMI. However, these metrics are blunt tools.

They cannot tell you:

• How much fat mass you’ve lost
• Whether you’re losing lean muscle
• Changes in visceral fat (the dangerous fat around organs)

Two people can lose the same weight but have completely different health outcomes depending on body composition.

A DEXA (Dual-energy X-ray Absorptiometry) scan provides a highly accurate breakdown of:

• Total body fat percentage
• Lean muscle mass
• Visceral adipose tissue (VAT)
• Regional fat distribution (arms, legs, trunk)
• Muscle asymmetry

Unlike bioimpedance (InBody) or scales, DEXA is considered a gold-standard clinical tool.

GLP-1 and GIP-based treatments are highly effective. That said, weight loss is not purely fat.

In fact, clinical evidence shows that:

• A proportion of weight loss comes from lean mass (muscle)
• Rapid weight loss increases the risk of muscle depletion
• Muscle loss can negatively impact metabolism and long-term weight maintenance

Therefore, this is particularly relevant for:

• Patients losing >10–15 kg
• Those not resistance training
• Individuals with lower baseline muscle mass

Crucially, DEXA allows you to monitor this precisely, ensuring your weight loss remains metabolically healthy.

Not all fat is equal. Specifically, visceral fat is the most harmful type.

It is strongly associated with:

• Type 2 diabetes
• Cardiovascular disease
• Insulin resistance
• Metabolic syndrome

Encouragingly, medications like Mounjaro have a significant impact on visceral fat.

Evidence from the SURMOUNT Trials

In a DEXA sub-study of the SURMOUNT trials:

• Significant reductions in visceral adipose tissue (VAT) were observed
• Fat loss was greater in the abdominal (trunk) region
• Improvements correlated with better metabolic health markers

Taken together, this shows that weight loss drugs are not just reducing weight — they are improving fat distribution, particularly the most dangerous fat.

1. Ensure You’re Losing Fat — Not Muscle

DEXA differentiates between fat and lean mass.
As a result, you can adjust:

• Protein intake
• Resistance training
• Treatment strategy

2. Track Visceral Fat Changes

DEXA measures VAT directly.
Therefore, you can:

• Assess true cardiometabolic risk reduction
• Go beyond cosmetic weight loss
• Quantify internal health improvements

3. Personalise Your Treatment Plan

At DEXA London, results are clinically actionable.
For example, they can help:

• Optimise nutrition
• Refine training
• Support long-term maintenance

4. Objective Progress Tracking

Weight fluctuates. By contrast, DEXA provides:

• Repeatable measurements
• Visual reports
• Data-driven reassurance

For most patients:

• Baseline scan before starting treatment
• Follow-up every 6 months

This aligns with safe, measurable body composition changes.

At DEXA London, we provide:

• Gold-standard DEXA body composition scans
• Detailed reports including visceral fat analysis
• Clinically relevant interpretation (not just raw data)
• Convenient central London location (Harley Street)

Weight loss injections are powerful — but understanding what you are losing is just as important as how much you lose.

A DEXA scan transforms weight loss from guesswork into precision medicine:

• Protect muscle
• Target fat
• Improve long-term outcomes